Ann: AHZ RESPONDS TO MEDIA SPECULATION, page-2

MINNEAPOLIS, MN – Admedus Limited (ASX:AHZ) (Company or Admedus) notes the recent media speculation about the ongoing funding of Admedus Vaccines Pty Ltd and the Admedus Immunotherapies (AI) business run by it. That speculation suggests there has been a change in strategy by Admedus with respect to the ongoing funding of AI.

In fact, there has been no change in the Company’s approach to AI to that previously disclosed to ASX. As stated in the release to ASX of Admedus’ FY2017 financial results on 31 August 2017, AI has funding for the coming financial year. In that announcement, Admedus also stated that: ‘The board of AI are currently undertaking a review of the potential strategic options available to them to secure the continuing development of AI’s technologies in a manner that balances maximising their potential with returns for its shareholders.’

That position has not changed. Admedus remains the majority shareholder in Admedus Vaccines and will continue to explore options in respect of AI in order to return value to shareholders.

The Company also notes that AI does not contribute to the Company’s revenue in a material way and confirms that it is in compliance with ASX Listing Rule 3.1 (Continuous Disclosure).